IP Library Granted Patent US 11,020,428
Granted Patent B2
US 11,020,428 · App. 16/196,806 · Granted Jun 1, 2021

Combined organ and hematopoietic cells for transplantation tolerance of grafts

Inventors: Samuel Strober (Stanford, CA); Robert Lowsky (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K35/12A61K31/365A61K31/436A61K31/573A61K35/14A61K35/17A61K35/22A61K35/28A61K38/13A61K38/193A61K39/001A61K39/39541A61K41/00A61K45/06A61N5/10A61K39/395A61K2035/122A61K2035/124A61K2039/515A61K2039/54A61K2039/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,428
App. No.
16/196,806
Granted
Jun 1, 2021
Kind
B2
Abstract

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Claims (13)

1. A method of manufacturing a cellular product for establishing mixed chimerism in a solid organ transplant recipient, the method comprising:

obtaining one or more samples comprising CD34+ cells and CD3+ cells;

processing the one or more samples to substantially remove platelets and red blood cells; and

further processing the one or more samples to produce a cellular product comprising greater than 5×105 CD34+ cells/kg recipient weight, and greater than 1×105 CD3+ cells/kg recipient weight, wherein the cellular product is substantially devoid of platelets and red blood cells.

2. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight.

3. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 1×106 CD3+ cells/kg recipient weight.

4. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight and about 1×106 CD3+ cells/kg recipient weight.

5. The method of claim 1 , wherein the one or more samples are further processed such that the cellular product comprises at least about 4×106 CD34+ cells/kg recipient weight and at least about 1×106 CD3+ cells/kg recipient weight.

6. The method of claim 1 , wherein the cellular product is produced such that the CD34+ cells and the CD3+ cells are provided in separate containers.

7. The method of claim 1 , wherein the cellular product is produced such that the CD34+ cells and the CD3+ cells are provided as a mixture in a common container.

8. The method of claim 1 , wherein the CD34+ cells and the CD3+ cells are HLA matched to an HLA type of the solid organ transplant recipient.

9. The method of claim 1 , wherein the CD34+ cells and the CD3+ cells are HLA mismatched to an HLA type of the solid organ transplant recipient.

10. The method of claim 1 , wherein CD34+ cells and the CD3+ cells are from a single apheresis product.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2018
From: STROBER, SAMUEL; LOWSKY, ROBERT
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 047707/0976 →
Continuity (5)
Continuation 15914736 · Mar 7, 2018
Continuation 15387292 · Dec 21, 2016
Continuation 14438159
Provisional Application 61769596 · Feb 26, 2013
Related Publication 20190083530A1 · Mar 21, 2019
Cited By (1)
US 12,245,355